{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:51:57Z","timestamp":1789851117690,"version":"4.0.1"},"reference-count":17,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T00:00:00Z","timestamp":1404691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis overlap is an acute hypersensitivity reaction that compromises the integrity of mucous membranes and cutaneous tissue. While the pathophysiology of this syndrome has not been fully elucidated, it is commonly associated with the medication use and carries a significant mortality risk of approximately 30%. No commonalities among causative medications have been identified, and determining the offending agent can be challenging. This case report describes fatal Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis overlap in a patient after receiving his first cycle of allopurinol, rituximab, and bendamustine treatment for non-Hodgkin\u2019s B-cell lymphoma. An analysis of FDA Medwatch adverse reaction case reports involving allopurinol, rituximab, and bendamustine is also presented.<\/jats:p>","DOI":"10.1177\/1078155214533368","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T20:35:46Z","timestamp":1404851746000},"page":"388-392","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Fatal Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis induced by allopurinol\u2013rituximab\u2013bendamustine therapy"],"prefix":"10.1177","volume":"21","author":[{"given":"Michael J","family":"Fallon","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics F6\/133, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N","family":"Heck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin School of Pharmacy, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,7,7]]},"reference":[{"key":"bibr1-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.05.002"},{"key":"bibr2-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31821201ed"},{"key":"bibr3-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.03.006"},{"key":"bibr4-1078155214533368","doi-asserted-by":"publisher","DOI":"10.5070\/D385N6C9JF"},{"key":"bibr5-1078155214533368","first-page":"207","volume":"50","author":"Bashir S","year":"2000","journal-title":"J Pak Med Assoc"},{"key":"bibr6-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91807-5"},{"key":"bibr7-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.021"},{"key":"bibr8-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-118"},{"key":"bibr9-1078155214533368","unstructured":"Genentech Inc. Rituxan (package insert). South San Francisco: Genentech Inc, 2013."},{"key":"bibr10-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf350"},{"key":"bibr11-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr254"},{"key":"bibr12-1078155214533368","unstructured":"Teva Pharmaceuticals Inc. Treanda (package insert). North Wales, PA: Teva Pharmaceuticals Inc, 2013."},{"key":"bibr13-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"bibr14-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7457.101"},{"key":"bibr15-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr16-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x"},{"key":"bibr17-1078155214533368","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.3.323"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155214533368","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155214533368","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155214533368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:15:40Z","timestamp":1777688140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155214533368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,7]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1177\/1078155214533368"],"URL":"https:\/\/doi.org\/10.1177\/1078155214533368","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,7]]}}}